These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 7621593)

  • 1. Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE).
    Marquart HV; Svendsen A; Rasmussen JM; Nielsen CH; Junker P; Svehag SE; Leslie RG
    Clin Exp Immunol; 1995 Jul; 101(1):60-5. PubMed ID: 7621593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus.
    Wilson JG; Ratnoff WD; Schur PH; Fearon DT
    Arthritis Rheum; 1986 Jun; 29(6):739-47. PubMed ID: 2941021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement-activating ability of leucocytes from patients with complement factor I deficiency.
    Marquart HV; Rasmussen JM; Leslie RG
    Immunology; 1997 Jul; 91(3):486-92. PubMed ID: 9301541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells.
    Olesen EH; Johnson AA; Damgaard G; Leslie RG
    Immunology; 1998 Feb; 93(2):177-83. PubMed ID: 9616366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
    Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
    J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement activation by malignant B cells from patients with chronic lymphocytic leukaemia (CLL).
    Marquart HV; Grønbaek K; Christensen BE; Svehag SE; Leslie RG
    Clin Exp Immunol; 1995 Dec; 102(3):575-81. PubMed ID: 8536375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) in promoting C3 fragment deposition and membrane attack complex formation on normal peripheral human B cells.
    Nielsen CH; Pedersen ML; Marquart HV; Prodinger WM; Leslie RG
    Eur J Immunol; 2002 May; 32(5):1359-67. PubMed ID: 11981823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
    Marquart HV; Svehag SE; Leslie RG
    J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3.
    Vik DP; Fearon DT
    J Immunol; 1985 Apr; 134(4):2571-9. PubMed ID: 3156185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematin promotes complement alternative pathway-mediated deposition of C3 activation fragments on human erythrocytes: potential implications for the pathogenesis of anemia in malaria.
    Pawluczkowycz AW; Lindorfer MA; Waitumbi JN; Taylor RP
    J Immunol; 2007 Oct; 179(8):5543-52. PubMed ID: 17911641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced numbers of complement receptor type 1 on erythrocytes are associated with increased levels of anticardiolipin antibodies. Findings in patients with systemic lupus erythematosus and the antiphospholipid syndrome.
    Hammond A; Rudge AC; Loizou S; Bowcock SJ; Walport MJ
    Arthritis Rheum; 1989 Mar; 32(3):259-64. PubMed ID: 2522783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.
    Kao AH; Navratil JS; Ruffing MJ; Liu CC; Hawkins D; McKinnon KM; Danchenko N; Ahearn JM; Manzi S
    Arthritis Rheum; 2010 Mar; 62(3):837-44. PubMed ID: 20187154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes.
    Nielsen CH; Marquart HV; Prodinger WM; Leslie RG
    Immunology; 2001 Dec; 104(4):418-22. PubMed ID: 11899427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of leukocyte CR1 gene transcription with the disease severity and renal involvement in systemic lupus erythematosus.
    Verma J; Arora V; Marwaha V; Kumar A; Das N
    Lupus; 2005; 14(4):273-9. PubMed ID: 15864913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low number of complement C3b/C4b receptors (CR1) on erythrocytes from patients with essential mixed cryoglobulinemia, systemic lupus erythematosus and rheumatoid arthritis: relationship with disease activity, anticardiolipin antibodies, complement activation and therapy.
    Corvetta A; Pomponio G; Bencivenga R; Luchetti MM; Spycher M; Spaeth PJ; Danieli G
    J Rheumatol; 1991 Jul; 18(7):1021-5. PubMed ID: 1833542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE).
    Levy E; Ambrus J; Kahl L; Molina H; Tung K; Holers VM
    Clin Exp Immunol; 1992 Nov; 90(2):235-44. PubMed ID: 1424280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
    Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
    J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
    Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
    J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hind III genomic polymorphism of the C3b receptor (CR1) in patients with SLE: low erythrocyte CR1 expression is an acquired phenomenon.
    Kumar A; Kumar A; Sinha S; Khandekar PS; Banerjee K; Srivastava LM
    Immunol Cell Biol; 1995 Oct; 73(5):457-62. PubMed ID: 8595925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of complement receptor type 1 (CD35) and decay-accelerating factor (CD55) on complement receptor type 2- (CD21) mediated alternative pathway activation by B cells.
    Leslie RG
    Immunology; 1999 Jul; 97(3):371-3. PubMed ID: 10447756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.